Volume 8, Number 4—April 2002
Research
Laboratory Reporting of Staphylococcus aureus with Reduced Susceptibility to Vancomycin in United States Department of Veterans Affairs Facilities1
, Linda H. Danko*†, and Gary A. Roselle*†‡
Table 1
Information from reported isolates of Staphylococcus aureus with reduced susceptibility to vancomycin from United States Veterans Health Administration medical facilities, FFYa 1999
| Case | Inpt/Outpt/NHb | Specimen | Methodc (Instrumentation/panel) | MIC/susceptibilityd | Confirmation of susceptibility | Confirmation methodology |
|---|---|---|---|---|---|---|
| 1 | Outpt | Ear tissue | MicroScan Walkaway version 22.01/Gram Pos Combo Panel 10 | > 16 μg/mL/R | Yes | MicroScan Walkaway |
| 2 | Inpt/SICUe | ABDf and VPg shunt | MicroScan Walkaway version 22.06/Pos Combo 12 | = 4 μg/mL/S | No | -- |
| 3 | Inpt | Sputum | MicroScan Walkaway version 22.26/Pos Combo 14 | = 4 μg/mL/S | No | -- |
| 4 | Outpt | Urine | MicroScan Walkaway version 22.06/Pos Combo 12 | = 4 μg/mL/S | No | -- |
| 5 | Outpt | Leg | MicroScan Walkaway/Pos Combo Panel 10 | = 4 μg/mL/S | No | -- |
| 6 | Outpt | Eye | MicroScan Walkaway/Pos Combo Panel 10 | = 8 μg/mL/(I) | No | -- |
| 7 | Inpt | Peritoneal | MicroScan Walkaway/Pos Combo Panel 10 | = 4 μg/mL/S | No | -- |
| 8 | Inpt | Urine | MicroScan Walkaway/Pos Combo Panel 10 | = 4 μg/mL/S | No | -- |
| 9 | Outpt | Wound | MicroScan AutoScan/Pos Combo 11 | = 4 μg/mL/S | No | -- |
| 10 | NH | Sputum | MicroScan AutoScan/Pos Combo 11 | = 4 μg/mL/S | No | -- |
| 11 | NH | Sputum | MicroScan AutoScan/Pos Combo 11 | = 4 μg/mL/S | No | -- |
| 12 | NH | Urine | MicroScan AutoScan/Pos Combo 11 | = 4 μg/mL/S | No | -- |
| 13 | NH | Urine | MicroScan AutoScan/Pos Combo 11 | = 4 μg/mL/S | No | -- |
| 14 | NH | Wound | MicroScan AutoScan/Pos Combo 11 | = 4 μg/mL/S | No | -- |
| 15 | Inpt | Foot wound | E-test; VCNh screen plate | = 4 μg/mL/S | Yes | Sent to CDCi; E-test |
| 16 | Outpt | Synovial fluid | MicroScan Walkaway/Gram Pos Combo Panel 10 | = 4 μg/mL/S | No | -- |
| 17 | Inpt/MICUj | Sputum | MicroScan Walkaway/Gram Pos Combo Panel 10 | = 4 μg/mL/S | No | -- |
| 18 | Inpt/ICUk | Blood | MicroScan AutoScan version 22.01/Pos Combo Panel 10 | = 4 μg/mL/S | No | -- |
| 19 | Inpt/MICU | Urine | BioMerieux Vitek VTK-R version 07.01/GPS-102 | > 32 μg/mL/R | Unable to determine | -- |
aFFY=Federal fiscal year.
bInpt=inpatient; Outpt=outpatient; NH=nursing home.
c bioMerieux Vitek (Hazelwood, MO), E-test (AB Biodisk North America, Inc., Piscataway, NJ), MicroScan (Dade Behring Inc., MicroScan Division, West Sacramento, CA). Where data were available, software version of technology provided. All MicroScan methods used conventional 24-hour incubation susceptibility panels.
d Susceptibility interpretation at the reporting site (S=sensitive, I=intermediate, R=resistant).
e SICU=surgical intensive care unit.
fABD=abdominal.
gVP=Ventriculo-peritoneal.
hVCN=vancomycin.
ICDC=Centers for Diseases Control and Prevention.
jMICU=medical intensive care unit.
kICU=intensive care unit.
1A portion of this material was presented at the 11th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America in Toronto, Ontario, Canada (Abstract #49), April 2001.